Chemical Formula: C13H20N4O3

Chemical Formula C13H20N4O3

Found 13 metabolite its formula value is C13H20N4O3

Lisofylline

1-(5-hydroxyhexyl)-3,7-dimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione

C13H20N4O3 (280.15353300000004)


   

Albifylline

1-(5-hydroxy-5-methylhexyl)-3-methyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione

C13H20N4O3 (280.15353300000004)


D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents > D001993 - Bronchodilator Agents C78273 - Agent Affecting Respiratory System > C29712 - Anti-asthmatic Agent > C319 - Bronchodilator D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents

   

Lisofylline

3,7-dihydro-1-(5-hydroxyhexyl)-3,7-dimethyl-1H-purine-2,6-dione

C13H20N4O3 (280.15353300000004)


D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D007155 - Immunologic Factors > D007166 - Immunosuppressive Agents D002491 - Central Nervous System Agents > D000700 - Analgesics C471 - Enzyme Inhibitor > C744 - Phosphodiesterase Inhibitor D011838 - Radiation-Sensitizing Agents D000893 - Anti-Inflammatory Agents D018501 - Antirheumatic Agents

   

(R)-Lisofylline

3,7-dihydro-1-[(5R)-5-hydroxyhexyl]-3,7-dimethyl-1H-purine-2,6-dione

C13H20N4O3 (280.15353300000004)


A 1-(5-hydroxyhexyl)-3,7-dimethyl-3,7-dihydro-1H-purine-2,6-dione that has (R)-configuration. A synthetic small molecule which was under development for the treatment of type 1 diabetes mellitus.

   

(S)-Lisofylline

3,7-dihydro-1-[5S-hydroxyhexyl]-3,7-dimethyl-1H-purine-2,6-dione

C13H20N4O3 (280.15353300000004)


A 1-(5-hydroxyhexyl)-3,7-dimethyl-3,7-dihydro-1H-purine-2,6-dione that has (S)-configuration. It is the inactive optical enantiomer of (R)-lisofylline, an anti-inflammatory agent.

   

(R)-TERT-BUTYL (1-OXO-1-(2-(PYRIDIN-2-YL)HYDRAZINYL)PROPAN-2-YL)CARBAMATE

(R)-TERT-BUTYL (1-OXO-1-(2-(PYRIDIN-2-YL)HYDRAZINYL)PROPAN-2-YL)CARBAMATE

C13H20N4O3 (280.15353300000004)


   

(S)-TERT-BUTYL (1-OXO-1-(2-(PYRIDIN-2-YL)HYDRAZINYL)PROPAN-2-YL)CARBAMATE

(S)-TERT-BUTYL (1-OXO-1-(2-(PYRIDIN-2-YL)HYDRAZINYL)PROPAN-2-YL)CARBAMATE

C13H20N4O3 (280.15353300000004)


   

Ciclosidomine

Ciclosidomine

C13H20N4O3 (280.15353300000004)


C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic C78274 - Agent Affecting Cardiovascular System > C29707 - Vasodilating Agent D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents

   

tert-butyl 4-(5-hydroxypyrimidin-2-yl)piperazine-1-carboxylate

tert-butyl 4-(5-hydroxypyrimidin-2-yl)piperazine-1-carboxylate

C13H20N4O3 (280.15353300000004)


   

TERT-BUTYL 2-AMINO-4-HYDROXY-8,9-DIHYDRO-5H-PYRIMIDO[4,5-D]AZEPINE-7(6H)-CARBOXYLATE

TERT-BUTYL 2-AMINO-4-HYDROXY-8,9-DIHYDRO-5H-PYRIMIDO[4,5-D]AZEPINE-7(6H)-CARBOXYLATE

C13H20N4O3 (280.15353300000004)


   

2-Methyl-2-propanyl 4-(4-formyl-1H-1,2,3-triazol-1-yl)-1-piperidi necarboxylate

2-Methyl-2-propanyl 4-(4-formyl-1H-1,2,3-triazol-1-yl)-1-piperidi necarboxylate

C13H20N4O3 (280.15353300000004)


   

Deuterated s-lisofylline

Deuterated s-lisofylline

C13H20N4O3 (280.15353300000004)


   

1-(5-hydroxyhexyl)-3,7-dimethyl-3,7-dihydro-1H-purine-2,6-dione

1-(5-hydroxyhexyl)-3,7-dimethyl-3,7-dihydro-1H-purine-2,6-dione

C13H20N4O3 (280.15353300000004)


A dimethylxanthine that is 3,7-dihydro-1H-purine-2,6-dione which is substituted at positions 1,3 and 7 by a 5-hydroxyhexyl group, methyl group and methyl group, respectively.